Evidence from randomised controlled trials (RCTs) indicates that corticosteroids significantly improve muscle strength and function in boys with Duchenne muscular dystrophy (DMD) in the short term (six months), and strength at two years (two-year data on function are very limited). Corticosteroids, now part of care recommendations for DMD, are largely in routine use, although questions remain over their ability to prolong walking, when to start treatment, longer-term balance of benefits versus harms, and choice of corticosteroid or regimen. This updated review now includes comparisons of different corticosteroids and dosing regimens. It examined the effects of corticosteroids on prolongation of walking ability, muscle strength, functional ability, and quality of life in DMD; addressed the question of whether benefit is maintained over the longer term (more than two years); assessed adverse events; and compared efficacy and adverse effects of different corticosteroid preparations and regimens.
